[Historical Review of Kaposi sarcoma in pre-HAART era: evolution with different chemotherapy schedules and remission with ganciclovir use]. / Revisión histórica del sarcoma de Kaposi en la era pre-TARAA (terapia antirretroviral altamente activa): evolución con diferentes esquemas de quimioterapia y remisión con el uso de ganciclovir.
Gac Med Mex
; 152(Suppl 2): 96-102, 2016 Oct.
Article
em Es
| MEDLINE
| ID: mdl-27792721
ABSTRACT
Ganciclovir has shown in vitro anti-human herpesvirus-8 activity, Kaposi sarcoma agent. We analyzed all Kaposi sarcoma patients from 1985 to 1996 pre-HAART era and identified Kaposi sarcoma/AIDS patients who achieved complete remission prior to HAART use. RESULTS:
We saw 155 Kaposi sarcoma patients up to 1996, 150 with enough information, only 12 received ganciclovir, eight of them for ≥ 21 days; four died within 16 weeks of ganciclovir administration. We identified four male patients with extensive Kaposi sarcoma with complete remission achieved after ganciclovir for CMV end-organ disease. Complete remission was achieved (9, 5, 10 and 5 months) after ganciclovir, which persisted even after antiretroviral therapy failure. All received two nucleosides and indinavir was later added with irregular compliance. The CD4 counts when ganciclovir was started 11 (4%), 60 (5%), 127 (14%), and 38 (3%) and when they achieved complete remission 37 (4%), 109 (9%), 313 (13%) and 136 (9%), respectively. Two patients died with no Kaposi sarcoma relapse three years later, with wasting syndrome and other pulmonary-embolism seven years later. One was lost to follow-up in complete remission in the year 2000, the other was alive in 2014 with 27% 820 CD4 cells/ml. The use of ganciclovir was statistically significantly associated with Kaposi sarcoma remission p = 0.001.CONCLUSIONS:
Ganciclovir use was associated to complete remission of Kaposi sarcoma in the pre-HAART era.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Sarcoma de Kaposi
/
Ganciclovir
/
Terapia Antirretroviral de Alta Atividade
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Mexico
Idioma:
Es
Revista:
Gac Med Mex
Ano de publicação:
2016
Tipo de documento:
Article